Skip to main content
SpringerLink
Log in

Analytic Vaccinology: Antibody-Driven Design of a Human Cytomegalovirus Subunit Vaccine

  • Protocol
  • First Online:
Vaccine Design

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1403))

Abstract

Identification of the most relevant protective antigens has represented a considerable obstacle for the development of subunit vaccines against viral infections, including human cytomegalovirus (HCMV) infection. This chapter describes the method of analytic vaccinology, centered on the clonal analysis of human B cell response to HCMV, which represents an essential tool for assessing the impact of individual viral antigens in the antiviral antibody response. By providing key information on the immunogenicity and protective properties of the antibodies elicited by viral proteins, the analytic vaccinology method guides the selection of the most appropriate vaccine candidates. Here we discuss methodologies for the generation of human monoclonal antibodies from B cells of immune donors, antibody screening in in vitro assays of antigen binding and virus neutralization, and strategies of animal immunization useful for the preclinical evaluation of selected viral antigens. The approach of analytic vaccinology could be universally applied to the characterization of B-cell immune response against any virus of interest and ultimately used for vaccine development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kabanova A, Perez L, Lilleri D et al (2014) Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A 111:17965–17970

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231–243

    Article  CAS  PubMed  Google Scholar 

  3. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–742

    Article  CAS  PubMed  Google Scholar 

  4. Griffiths PD, Stanton A, McCarrell E et al (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 377:1256–1263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lilleri D, Kabanova A, Revello MG et al (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gh/gl/pul128-130-131 complex during primary infection. PLoS One 8(3):e59863

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Traggiai E, Becker S, Subbarao K et al (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875

    Article  CAS  PubMed  Google Scholar 

  7. Traggiai E (2012) Immortalization of human B Cells: analysis of B cell repertoire and production of human monoclonal antibodies. Methods Mol Biol 901:161–170

    Article  CAS  PubMed  Google Scholar 

  8. Tiller T, Meffre E, Yurasov S et al (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329:112–124

    Article  CAS  PubMed  Google Scholar 

  9. Smith K, Garman L, Wrammert J et al (2009) Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 4:372–384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hahn G, Revello MG, Patrone M et al (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78:10023–10033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ryckman BJ, Rainish BL, Chase MC et al (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82:60–70

    Article  CAS  PubMed  Google Scholar 

  12. Ciferri C, Chandramouli S, Donnarumma D et al (2015) Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc Natl Acad Sci 112:1767–1772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yamane Y, Furukawa T, Plotkin SA (1983) Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus. Vaccine 1:23–25

    Article  CAS  PubMed  Google Scholar 

  14. Bowden RA, Slichter SJ, Sayers M et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598–3603

    CAS  PubMed  Google Scholar 

  15. Lipson SM, Shepp DH, Match ME et al (2001) Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol 116:52–55

    Article  CAS  PubMed  Google Scholar 

  16. Gerna G, Percivalle E, Baldanti F et al (2000) Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 74:5629–5638

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gerna G, Sarasini A, Patrone M et al (2008) Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89:853–865

    Article  CAS  PubMed  Google Scholar 

  18. Krashias G, Simon AK, Wegmann F et al (2010) Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer. Vaccine 28:2482–2489

    Article  CAS  PubMed  Google Scholar 

  19. Lai RP, Seaman MS, Tonks P et al (2012) Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to freund’s adjuvants. PLoS One 7(4):e35083

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Grazia Revello M, Baldanti F, Percivalle E et al (2001) In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol 82:1429–1438

    Article  CAS  PubMed  Google Scholar 

  21. Gerna G, Baldanti F, Percivalle E et al (2003) Early identification of human cytomegalovirus strains by the shell vial assay is prevented by a novel amino acid substitution in UL123 IE1 gene product. J Clin Microbiol 41:4494–4495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Macagno A, Bernasconi NL, Vanzetta F et al (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH / gL / UL128-131A complex. J Virol 84:1005–1013

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This chapter described work conducted at the Institute for Research in Biomedicine (Bellinzona, Switzerland). The project was partially supported by Fondazione CARIPLO Grant 93043/A, Fondazione Carlo Denegri, Swiss National Science Foundation grant 141254, Ministero della Salute grant RF-2010-GR-2010-2311329, and Mäxi Foundation.

Author information

Authors and Affiliations

  1. Department of Life Sciences, University of Siena, via Aldo Moro 2, Siena, 53100, Italy

    Anna Kabanova

  2. Laboratori Sperimentali di Ricerca, Area Trapiantologica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, Italy

    Daniele Lilleri

Authors
  1. Anna Kabanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniele Lilleri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Anna Kabanova or Daniele Lilleri .

Editor information

Editors and Affiliations

  1. Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

    Sunil Thomas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Kabanova, A., Lilleri, D. (2016). Analytic Vaccinology: Antibody-Driven Design of a Human Cytomegalovirus Subunit Vaccine. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1403. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3387-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3387-7_8

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3385-3

  • Online ISBN: 978-1-4939-3387-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation